Inflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 16–22, 2024, as Inflammatory Eye Disease Awareness Week. There are several inflammatory eye conditions. The one we specialize in at Texas Retina is called uveitis [u-vee-i-tis]. Understanding
read moreDr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read moreDr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read moreInflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 18 – 24, 2023, as Inflammatory Eye Disease Awareness Week. There are a number of inflammatory eye conditions. The one we specialize in at Texas Retina Associates
read moreFour New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read moreDr. Wang Co-authored Article on New Non-infectious Uveitis Treatment Published in Acta Ophthalmologica Journal
Texas Retina Associates’ Robert C. Wang, MD, co-authored an article titled “Management of Repository Corticotropin Injection Therapy for Non‐infectious Uveitis: A Delphi Study” in the March 2021 issue of the medical journal
read more